Standardization of Uveitis Nomenclature for Reporting Clinical Data. Results of the First International Workshop

Jabs, Douglas A.; Nussenblatt, Robert B.; Rosenbaum, James T.

doi:10.1016/j.ajo.2005.03.057

Cited by 3,356 publications

(994 citation statements)

References 21 publications

Supporting

Mentioning

971

Contrasting

Unclassified

Order By: Relevance

“…There are currently no agreed guidelines for describing uveitis-related systemic conditions. 9 A summary of uveitis classification according to the SUN criteria 8 is presented in Table 1.…”

Section: Description Of the Health Problemmentioning

confidence: 99%

“…36 The SUN system was a formalisation and adoption of the Nussenblatt scale. 8,37 Grading requires the examination of a patient's eye by an indirect ophthalmoscope followed by a comparison of the appearance with a series of photographs of varying grades of fundus VH. 37 Although the grading system is accepted by the US Food and Drug Administration and has been used in a number of recent studies of uveitis, 36 it is a subjective grading of cloudiness in the vitreous humour caused by inflammatory cells and cell debris on a non-continuous scale (0, 0.5+, 1, 2, 3 and 4+).…”

Section: Measurement Of Diseasementioning

confidence: 99%

“…7 These were later revised in 2004 following the Standardization of Uveitis Nomenclature (SUN) Workshop. 8 The SUN criteria included onset, duration and course of uveitis in the classification of the condition. There are currently no agreed guidelines for describing uveitis-related systemic conditions.…”

Section: Description Of the Health Problemmentioning

confidence: 99%

See 2 more Smart Citations

A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults

Squires

Poku

Bermejo

et al. 2017

Health Technol Assess

View full text Add to dashboard Cite

Declared competing interests of authors: Fahd Quhill has received personal fees from Allergan for participation in medical education and training, and has participated in advisory boards given his clinical expertise in the role of steroids in diabetic macular oedema. He has also received support from Allergan to attend international conferences.Published November 2017 DOI: 10.3310/hta21680 This report should be referenced as follows: This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).Editorial contact: journals.library@nihr.ac.ukThe full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Health Technology Assessment journalReports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.Reviews in Health Technology Assessment are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others. HTA programmeThe HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta This reportThe research reported in this issue of the journal was commissioned and funded by the HTA programme on behalf of NICE as project number 15/64/07. The protocol was agreed in June 2016. The assessment report began editorial review in December 2016 and was accepted for publication in May 2017. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expre...

show abstract

“…There are currently no agreed guidelines for describing uveitis-related systemic conditions. 9 A summary of uveitis classification according to the SUN criteria 8 is presented in Table 1.…”

Section: Description Of the Health Problemmentioning

confidence: 99%

Section: Measurement Of Diseasementioning

confidence: 99%

See 1 more Smart Citation

A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults

Squires

Poku

Bermejo

et al. 2017

Health Technol Assess

View full text Add to dashboard Cite

show abstract

“…In the prevalent sample, a subgroup of persistent NIIPPU cases was defined as those receiving treatment for NIIPPU for ≥90 days (corticosteroids, traditional immunosuppressants and/or biologic therapy) (Jabs et al. 2005). …”

Section: Methodsmentioning

confidence: 99%

“…The Standardization of Uveitis Nomenclature (SUN) guidelines classify uveitis by anatomic location as anterior, intermediate, posterior or panuveitis (Jabs et al. 2005); hereafter, non‐infectious intermediate, posterior and panuveitis will be referred to collectively as NIIPPU. Compared with anterior disease, which is the most common non‐infectious form (Chang & Wakefield 2002; Gritz & Wong 2004; Acharya et al.…”

Section: Introductionmentioning

confidence: 99%

Direct and indirect resource use, healthcare costs and work force absence in patients with non‐infectious intermediate, posterior or panuveitis

Thorne

Skup

Tundia

et al. 2016

Acta Ophthalmologica

View full text Add to dashboard Cite

PurposeTo ascertain resource use, costs and risk of workforce absence in non‐infectious uveitis cases versus matched controls.MethodsIn a retrospective claims analysis of employees in the United States, prevalent (N = 705) and incident (N = 776) cases 18–64 years old with ≥2 diagnoses of non‐infectious intermediate, posterior or panuveitis were matched 1:1 to controls without uveitis. Persistent prevalent cases (treated for ≥90 days, N = 112) also were analysed. Outcomes were annual direct resource use and costs associated with inpatient stays; emergency department, outpatient and ophthalmologist/optometrist visits; and prescription drugs. Indirect resource use and costs associated with work loss from disability and medically related absenteeism also were compared. Multivariate regression assessed cost differences between cases and controls.ResultsCases had significantly (p < 0.05) more medical resource use versus controls including 0.4 versus 0.2 emergency visits and 16.5 versus 7.6 outpatient/other visits. Cases used more prescription drugs (7.8 versus 4.1) and had more disability days (10.3 versus 4.6), medically related absenteeism days (8.5 versus 3.8), and work loss days (18.7 versus 8.4) than controls (all p < 0.05). Total direct ($12 940 versus $3730) and indirect ($3144 versus $1378) costs were higher in cases than controls (all p < 0.05). Results for persistent cases suggested greater utilization and associated cost and work loss burden. Compared with controls, cases had significantly greater risks of workforce absence, leave of absence and long‐term disability (all p < 0.05).ConclusionNon‐infectious intermediate, posterior or panuveitis, particularly persistent disease, is associated with substantial medical and work loss costs suggesting an unmet need for more effective treatments.

show abstract

Association of Inflammatory Eye Disease With Granuloma Annulare?

Brey¹,

Purkiss²,

Sehgal³

et al. 2008

Arch Dermatol

View full text Add to dashboard Cite

Standardization of Uveitis Nomenclature for Reporting Clinical Data. Results of the First International Workshop

Cited by 3,356 publications

References 21 publications

A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults

A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults

Direct and indirect resource use, healthcare costs and work force absence in patients with non‐infectious intermediate, posterior or panuveitis

Association of Inflammatory Eye Disease With Granuloma Annulare?

Contact Info

Product

Resources

About